Table 3.
Patient Characteristics.
| Age | median | 67 |
|---|---|---|
| Gender | Female: Male: |
14 (41%) 20 (59%) |
| Lymphoma | DLBCL: MCL: |
26 (76%) 8 (24%) |
| Ann Arbor Stage | I: II: III: IV: |
2 (5,9%) 4 (11,8%) 7 (20,6%) 21 (61,8%) |
| IPI | 1: 2: 3: 4: 5: |
6 (17,6%) 8 (23,5%) 8 (23,5%) 8 (23,5%) 4 (11,8%) |
| CAR T Product | Tisagenlecleucel: Brexucabtagene autoleucel: Axicabtagene ciloleucel: Lisocabtagene maraleucel: |
20 (58,8%) 8 (23,5%) 5 (14,7%) 1 (2,9%) |
| Bridging | (R)-Pola-Benda (R)-DHAP (R)-GemOx Radiation (R)-Pola (R)-Pixantrone (R)-Dexa-Cyclo Ibrutinib Nivolumab Venetoclax No bridging |
8 6 5 2 1 1 1 1 1 1 7 |
| TBRECIL (median) | Total: Nodal: Extranodal: |
12.5 cm 8.5 cm 0.8 cm |
| TBLugano (median) | Total: Nodal: Extranodal: |
4,030 mm2
2,125 mm2 282 mm2 |
| TBMTV (median) | Total: Nodal: Extranodal: |
330 mL 51 mL 24 mL |
| LDH (median) | Apheresis Prior Lymphodepletion |
356 U/L 296 U/L |
CAR; chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; MTV, metabolic tumor volume; RECIL, response evaluation criteria in lymphoma; TB, tumor burden.